Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.

Mylan Inc., Abbott Laboratories

News Well, MassDevice.com Earnings Roundup, 2014, Mergers & Acquisitions, Pharmaceuticals, Q3, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1x8WJNz